WO2001082977A1 - Liposomes contenant un compose iodo hydrophobe - Google Patents
Liposomes contenant un compose iodo hydrophobe Download PDFInfo
- Publication number
- WO2001082977A1 WO2001082977A1 PCT/JP2001/003629 JP0103629W WO0182977A1 WO 2001082977 A1 WO2001082977 A1 WO 2001082977A1 JP 0103629 W JP0103629 W JP 0103629W WO 0182977 A1 WO0182977 A1 WO 0182977A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- smooth muscle
- ribosome
- vascular smooth
- muscle cells
- compound
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0438—Organic X-ray contrast-enhancing agent comprising an iodinated group or an iodine atom, e.g. iopamidol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
- A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
- A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
- A61K49/0461—Dispersions, colloids, emulsions or suspensions
- A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles
Definitions
- the present invention relates to ribosomes, and more specifically, to ribosomes that can be used in a method of selectively accumulating a hydrophobic oxidized compound at a diseased site and contrasting the non-disease site with an image.
- Background technology ''
- Diagnosis methods for arteriosclerosis are broadly classified into non-invasive methods and invasive methods in which a catheter or the like is inserted into an artery.
- the main non-invasive methods are X-ray angiography and ultrasound, but early stage arteriosclerosis, especially stenosis of the coronary arteries that causes myocardial infarction and angina at an early stage. Is almost impossible to detect.
- Other non-invasive methods, such as CT and MRI may also be used, but these methods were developed primarily for tumor detection and not only have problems with the resolution of atherosclerotic lesions, The number of hospitals that can be implemented is limited due to the need for expensive and large-scale equipment, and they are not generally used.
- a method using a radioisotope is also being studied, but it has not gone out of the experiment.
- X-ray angiography is the most widely used to identify arterial stenosis.
- a blood flow is contrasted by administering a water-soluble contrast medium, and a portion where the flow is blocked is found.
- this method usually only detects lesions with stenosis of 50% or more, and it is difficult to detect lesions before the onset of ischemic disease attacks.
- J. Pharm. Sci. 72 (8), 898 (1983) discloses an example of X-ray imaging of the liver and spleen by injection of an oil droplet dispersion of Cholesteryl Iopanoate.
- US Patent No. 4567034 reports a method of encapsulating an ester of dia rizoic acid in ribosomes and selectively imaging liver and spleen.
- International Publications W096 / 28414 and W096 / 00089 disclose contrast agents for imaging the vascular pool / lymphatic system. However, these preparation methods are not efficient or selective for the purpose of selectively imaging vascular disease, and are not suitable for X-ray irradiation. There have been no reports of imaging vascular disease.
- An object of the present invention is to provide a means for selectively accumulating an eodo compound at a vascular disease site caused by abnormal proliferation of vascular smooth muscle such as arteriosclerosis and restenosis after PTCA. It is another object of the present invention to image the in-vivo environment such as a vascular disease by X-ray contrast by using the means.
- the present inventors have conducted intensive studies to solve the above-mentioned problems, and as a result, it has been found that ribosomes containing a hydrophobic odo compound as one of the membrane components include vascular smooth muscle and foam which are the main components of atherosclerotic lesion Was found to accumulate in macrophages.
- Another object of the present invention is to provide a cell culture system that reproduces the state of a lesion such as arteriosclerosis and restenosis, and a method for producing the same. It is also an object of the present invention to provide a method for evaluating a drug for arterial disease by using this means.
- the present inventors have conducted studies to solve the above-mentioned problems, and as a result, by simultaneously culturing two or more types of cells that form a lesion in a mammal in the same cell incubator, an arteriosclerotic lesion or restenosis has been obtained. It has been found that it is possible to provide a cell culture system that reproduces the state of a lesion such as the above.
- the present invention has been completed based on the above findings.
- the present invention provides a ribosome containing a hydrophobic odo compound as a membrane component.
- a hydrophobic ode compound a ribosome which is a 1,3,5-triodobenzen derivative having at least one substituent having 18 or more carbon atoms, the ribosome; phosphatidylcholine and phosphatidylserine
- the ribosome containing a selected lipid as a membrane component; the ribosome containing a dialkyl phosphate, which is an alkyl diester having 6 or more carbon atoms, as a membrane component; and a cholesterol derivative having a substituent having 18 or more carbon atoms.
- an X-ray contrast agent containing the ribosome is provided.
- the above-mentioned X-ray for use in imaging vascular disease preferably vascular smooth muscle cells abnormally proliferating under the influence of foamed macrophages, such as atherosclerotic lesions and restenosis after PTCA
- a contrast agent is provided.
- the present invention provides a method for imaging a vascular disease, the method including a step of X-ray imaging using the ribosome, and the use of the ribosome for producing the X-ray contrast agent.
- the present invention provides a method for creating a culture system including a step of simultaneously culturing two or more cell types involved in the formation of a lesion of a mammalian disease in the same cell incubator.
- the above-mentioned method wherein the cell type is a primary cultured cell isolated from a living body or an established passage cell; the above-mentioned method, wherein the cell type is a primary cultured cell of a mammalian animal;
- a method as described above wherein the mammalian disease is a human disease is provided.
- the above method wherein at least one of the cell types is a cell involved in atherosclerotic lesion formation; the cell type is selected from the group consisting of macrophages, vascular smooth muscle cells, and vascular endothelial cysts
- the above-mentioned method selected; the above-mentioned method comprising the step of culturing two cell types in the same cell incubator with a cell filter therebetween; and the above-mentioned method wherein the two cell types are macrophages and vascular smooth muscle cells.
- a method in which two types of primary cultured mammalian cells to be provided are cultured in the same incubator while being separated by a cell filter, and a culture system that reproduces the state of an atherosclerotic lesion is provided.
- the present invention provides a cell culture system obtainable by the above-described method for producing a culture system.
- the present invention also provides a method for screening a drug using a cell culture system obtainable by the above-described method for preparing a culture system.
- the method comprises the step of measuring the effect of a drug on vascular smooth muscle cells grown by culturing foamed macrophages and vascular smooth muscle cells through a cell filter.
- a method for determining the efficacy of a drug and a step of measuring the effect of the drug on vascular smooth muscle cells grown by culturing foamed macrophages and vascular smooth muscle cells through a cell filter.
- the present invention provides a method for evaluating the transferability of a drug to a vascular disease lesion.
- FIG. 1 shows the results of induction of mouse vascular smooth muscle cell proliferation in the presence of mouse foamed macrophages. ' ⁇
- FIG. 2 shows a growth curve of mouse vascular smooth muscle cells when mouse foamed macrophages were not added.
- FIG. 3 shows the results of induction of proliferation of rat vascular smooth muscle cells in the presence of rat foamed macrophages.
- FIG. 4 shows the results of induction of the proliferation of egos vascular smooth muscle cells in the presence of egos foamed macrophages.
- FIG. 5 shows ribosome uptake by mouse vascular smooth muscle cells.
- (1) shows the results obtained by adding a ribosome preparation 3 days later and culturing for 1 day in the culture system without mouse foamed macrophages shown in Fig. 2;
- the results obtained by adding the ribosome preparation after 5 days and culturing for 1 day are shown;
- 3 shows the culture system adding the mouse foamed macrophage shown in Fig. 1 and culturing for 1 day after adding the ribosome preparation after 7 days.
- the results are shown below.
- FIG. 6 shows the results when an oil droplet suspension was used in place of the ribosome of the present invention.
- FIG. 7 shows the uptake of liposomes by rat vascular smooth muscle cells cultured under the culture conditions of FIG. (1), (2) and (3) are the same as in Fig. 5.
- FIG. 8 shows the uptake of liposomes by the egret vascular smooth muscle cells cultured under the culture conditions of FIG. (1), (2) and (3) are the same as in Fig. 5.
- FIG. 9 is a photograph showing the results of radiographic imaging of atherosclerotic lesions using the liposome of the present invention.
- “before administration” indicates the results before ribosome administration
- “immediately after administration” indicates the results immediately after ribosome administration.
- FIG. 10 is a photograph showing the result of imaging an arteriosclerotic lesion by X-ray photography using the ribosome of the present invention.
- “15 minutes after administration” indicates the results 15 minutes after ribosome administration
- “30 minutes after administration” indicates the results 30 minutes after ribosome administration.
- the type of the hydrophobic chloride compound is not particularly limited.
- a chloride benzene derivative is preferable, and is a 1,3,5-triodebenzene derivative having at least one substituent having 18 or more carbon atoms. Is more preferable.
- the substituent having 18 or more carbon atoms is a hydrophobic group that enables the 1,3,5-triodobenzene residue, which is a part of the pseudo-imaging, to be stably present in the lipid bilayer of the liposome.
- the number of carbon atoms is 20 or more and the total number of oxygen atoms and nitrogen atoms is 10 or less.
- the hydrophobic substituent has a structure similar to that of a constituent component of a biological membrane lipid.
- Preferred examples of hydrophobic odor compounds satisfying these conditions include, for example, J. Med. Chem. 25 (12), 1500 (1982); Steroids 49 (6), 531 (1987); Pharm. Res. 6 (12 ), 1011 (1989); International Publication TO95 / 19186; and 1,3,5-triiodobenzene derivatives having a residue of a cholesterol derivative disclosed in WO096 / 28414 and the like as a substituent.
- cholesterol derivative those disclosed in the above publications are preferable, Particularly preferred is cholesterol.
- a hydrophobic odo compound for example 1,3,5-triodobenzene.
- 1,3,5-triodebenzene for example, an ester bond, an ether bond, a urethane bond, a carbonate bond, or the like may be used. Yes, but ester bonds are preferred.
- Cholesterol and a hydrophobic chloride compound may be directly bonded via the above bond, or may be bonded via an appropriate linking group. Les ,.
- suitable linking groups include linear or branched alkylene groups having 5 or less carbon atoms.
- the hydrophobic chloride compound preferably 1,3,5-triodebenzene compound, may have one or more substituents in addition to the above-mentioned substituent having 18 carbon atoms. ,.
- the type and position of the substituent are not particularly limited. Is preferred. Preferred substituents are a substituted or unsubstituted amino group or a substituted or unsubstituted acylamino group.
- Examples of the case where the amino group has a substituent include a monoalkylamino group and a dialkylamino group. Examples of the case where the amino group has a substituent include a trifluoroacetylamino group and a p-chloroamino group. And an azoylamino group.
- hydrophobic odor compound Preferred examples of the hydrophobic odor compound are shown below, but the ribosome of the present invention is not limited to those containing these.
- Hydrophobic Yodo compounds contained as a membrane component of the ribosome, 1 0-9 about 0% by weight relative to the total weight of the membrane components, preferably preferably 1 0 to 8 0 wt 0/0, and et al 20 to 80% by mass.
- the hydrophobic chloride compound is a component of the membrane. One type may be used, or two or more types may be used in combination.
- any lipid compound commonly used in the production of liposomes can be used.
- Biochim. Biophys. Acta 150 (4), 44 (1982) Adv. In Lipid. Res. 16 (1) 1 (1978), "RESEARCH IN LIPOSOMES” (P. Machy, L. Leserman, John Libbey EUROTEXT), "Liposom” (Nojima, Sunamoto, Inoue, Nankodo), etc.
- Phospholipids are preferred as lipid compounds, and phosphatidylcholine (PC) is particularly preferred.
- Preferred examples of phosphatidylcholines include, but are not limited to, eggPC, dimyristril PC (DMPC), dipalmitoyl PC (DPPC), distearoyl PC (DSPC), and dioleyl PC (D0PC). .
- DMPC dimyristril PC
- DPPC dipalmitoyl PC
- DSPC distearoyl PC
- D0PC dioleyl PC
- phosphatidylcholine and phosphatidylserine can be used in combination as ribosome membrane components.
- the phosphatidylserine include compounds having a lipid moiety similar to the phospholipids mentioned as preferred examples of the phosphatidylcholine.
- a ribosome containing phosphatidylcholine and phosphatidylserine, and further containing a dialkyl phosphate is mentioned as a membrane component.
- the two alkyl groups constituting the dialkyl ester of the dialkyl phosphate are preferably the same, and each alkyl group has 6 or more carbon atoms, preferably 10 or more, and more preferably 12 or more.
- Ma Examples of preferred dialkyl phosphates include, but are not limited to, dilauryl phosphate, dimyristyl phosphate, dicetyl phosphate, and the like.
- the preferred use amount of the dialkyl phosphate is 1 to 50% by mass relative to the total mass of phosphatidylcholine and phosphatidylserine. / 0 , preferably 1 to 30% by mass. Preferably from 1 to 20 mass. / 0 .
- the preferable mass ratio of the above components is PC: PS: dialkyl phosphate: hydrophobic odo compound: 5 to 4 0% by mass: 5 to 40% by mass: 1 to 10% by mass: can be selected from 15 to 80% by mass.
- the components of the ribosome of the present invention are not limited to the above four, and other components can be added.
- examples thereof include cholesterol, cholesterol monoester, sphingomyelin, FEBS Lett. 223, 42 (1987); Proc. Natl. Acad. Sci., USA, 85, 6949 (1988) and the like. Derivatives, Chem. Lett., 2145 (1989); Glucuronic acid derivatives described in Biochim. Biophys. Acta, 1148, 77 (1992), etc., Biochim. Biophys. Acta, 1029, 91 (1990); FEBS Lett., 268, 235 (1990), etc., but not limited thereto.
- the ribosomes of the present invention can be made by any method known in the art.
- preparation method include, in addition to the above-mentioned review documents on liposomes, Ann. Rev. Biophys. Bioeng., 9, 467 (1980), "Liopsomes” (edited by MJ Ostro, MARCELL DEKKER, INC.), Etc. It is described in. Specific examples include an ultrasonic treatment method, an ethanol injection method, a french press method, an ether injection method, a cholic acid method, a calcium fusion method, a freeze-thaw method, a reverse phase evaporation method, and the like. Absent.
- the size of the liposome of the present invention may be the size or deviation of the size that can be produced by the above method, but usually the average is 400 nm or less, preferably 200 nm or less.
- the structure of the liposome is not particularly limited, and may be, for example, either lamella or multilamella. It is also possible to mix one or more appropriate drugs or other contrast agents inside the liposome.
- the ribosome of the present invention when used as a contrast agent, it can be preferably administered parenterally, more preferably intravenously.
- injection Preparations in the form of lyophilized solutions or infusions are provided as a powdered composition in lyophilized form, which can be dissolved or reconstituted in water or other suitable medium (eg, saline, dextrose infusion, buffer, etc.) before use. It can be used in suspension.
- the dose can be appropriately determined so that the eode content of the ribosome is almost the same as the eode content of the conventional aqueous aquatic contrast agent.
- vascular smooth muscle cells that form the lining of the blood vessels cause abnormal proliferation and It is known to migrate and narrow blood channels.
- the trigger for normal vascular smooth muscle cells to initiate abnormal proliferation has not been fully elucidated, but it is known that migration and foaming of macrophages to the intima are important factors, It has been reported that smooth cells undergo phenotype conversion (contracted to synthetic).
- the contrast agent of the present invention can be suitably used particularly for X-ray imaging of vascular diseases, and for example, can perform imaging of arteriosclerotic lesions and restenosis after PTCA.
- the imaging method is not particularly limited. Examples include, but are not limited to, a method by X-ray irradiation, or a nuclear medicine method using an eodo radiolabel.
- the method for preparing a culture system is characterized by including a step of culturing two or more cell types involved in the formation of a lesion of a mammalian disease in the same cell incubator.
- the cell type is preferably a primary cell culture or a subcultured cell line of the strain I, and a primary culture of mammalian cells is particularly preferred.
- Preferred mammals include, but are not limited to, humans, dogs, cats, pigs, minipigs, egrets, hamsters, rats, mice, and the like.
- the type of the cell incubator is not particularly limited, but, for example, a culture flask, a culture test tube, a petri dish, a microplate, and the like can be suitably used.
- the two or more different cell types to be cultured in the same incubator may be either of the same animal-derived or different animal-derived cell types, but are preferably of the same type.
- the term "participating in the formation of a lesion" must be interpreted in the broadest sense, including the case where a plurality of cells form a lesion while regulating the growth of each other, and is limited in any sense. Should not be interpreted.
- the different cell types it is preferable to select different cells from the viewpoint of cell biology or cell taxonomy, but two types that coexist in a lesion and form a lesion while regulating the growth of each other are used. More preferably, the cells are selected. For example, it is preferable to select macrophages and vascular smooth muscle cells coexisting in atherosclerotic lesions as two cell types.
- two cell types can be cultured in the same well while being separated by a cell filter.
- the two cell types used are preferably cells forming an arteriosclerotic lesion.
- Preferred cell types include macrophages, vascular smooth muscle cells, vascular endothelial cells, T cells, mast cells and the like.
- macrophages, vascular smooth muscle cells, and vascular endothelial cells are foamed in advance.
- the present invention provides a method for measuring the action of a drug on vascular smooth muscle cells grown by culturing foamed macrophages and vascular smooth muscle cells through a cell filter. It provides a method for assessing portability.
- drug action as used herein should be interpreted in the broadest sense, including therapeutic or diagnostic effects.
- the type of cell filter is not particularly limited as long as it has a pore size that does not allow foamed macrophages and vascular smooth muscle cells to pass through.
- a cell filter having a pore size of 0.4 ⁇ or less can be used as a pore size that does not allow cells to pass through, but a foamed macrophage can be used depending on the type of cells used. Can be easily selected.
- foamed macrophage-derived proliferative active substances can be converted into vascular smooth muscle cells. It acts on cells to induce proliferation and can reproduce in vitro the abnormal proliferation of vascular smooth muscle cells in vascular diseases such as arteriosclerosis and restenosis after PTCA.
- vascular diseases such as arteriosclerosis and restenosis after PTCA.
- Example 1 Creation of a vascular smooth muscle culture system that activates proliferation by foamed macrophages (1) Isolate vascular smooth muscle cells from mouse aortic endothelium (Tissue Culture Method Revised Large 10th Edition, Kodansha, 1998, Japan Edited by the Society of Tissue Culture). The separated vascular smooth muscle cells were suspended in 10% FBS single MEM medium (GIBC0, No. 11095-080) and seeded on a 12-well microplate (FALCON, No. 3503). At this time, the number of cells in each well was adjusted to 10,000 cells. The cells were cultured at 37 ° C. and 5% CO 2 for 3 days.
- FBS single MEM medium GIBC0, No. 11095-080
- FIG. 1 shows the number of vascular smooth muscle cells in the above experiment. The growth at the beginning of the culture was slow, but after 3 days after addition of foamed macrophage, the cells showed a vigorous growth through an induction period of about 1 day.
- FIG. 2 shows the growth curve of vascular smooth muscle cells when macrophages were not added. Comparison with Fig. 1 Example 2: Confirmation of scavenger receptor expression on vascular smooth muscle
- vascular smooth muscle cells in atherosclerotic lesions take up oxidized LDL by expressing a scavenger receptor on the surface (Biochem. Pharmacol. 1999, 15; 57 (4) 383-6: Exp. Mol. Pathol. 1997 64 (3) 127-45).
- Immunostaining was performed on the vascular smooth muscle cells in the culture system shown in Fig. 1 using a mouse scavenger receptor antibody. As a result, no expression was observed in the vascular smooth muscle cells on day 3 after seeding. On the sixth day after sowing, clear staining was confirmed. In addition, the immunostaining of the foamed macrophages on the cell filter was carried out in the same manner, and clear staining was also observed.
- Example 3 Uptake of acid LDL by vascular smooth muscle cells
- vascular smooth muscle cells cultured by the cell culture system of the present invention have properties similar to those of focal smooth muscle cells such as arteriosclerosis or restenosis.
- Example 4 Creation of a vascular smooth muscle culture system that activates proliferation by foamed macrophages (2)
- rat and egret macrophages and vascular smooth muscle A culture system consisting of cells was prepared.
- Fig. 3 and Fig. 4 show the number of vascular smooth muscle cells. In each case, the same results as in the mouse of FIG. 1 were obtained.
- the vascular smooth muscle cells cultured in the culture system shown in Fig. 1 have healthy vascular properties up to 3 days after seeding, and have the properties of smooth muscle cells in atherosclerotic lesions from 7 days after seeding. Therefore, by comparing the effects on both, it is possible to perform selective drug screening for the lesion. In particular, it can be used for searching for a drug delivery system that is selective for a lesion, for searching for a drug that exhibits selective toxicity for a lesion cell, and for developing a drug that selectively arrests the cell cycle of a lesion cell. Specific examples are shown below, but the present invention is not limited to these.
- Example 5 Ribosome preparation
- egg PC Fertoshi, No. 1 2 01- 41- 0 2 14
- egg PS Fna stiffness Co., No. 1201-42-02266
- DCP dicetyl phosphate
- the hydrophobic chloride compounds (3) synthesized by the method described in Funakoshi Co., No. 1354- 14-8165) and J. Med. Chem., 25 (12), 1500 (1982) are each placed in an eggplant-shaped flask. After dissolving in methylene chloride to obtain a homogeneous solution, the solvent was distilled off under reduced pressure to form a thin film on the bottom of the flask. After drying the thin film in a vacuum, 1.5 ml of 0.9% physiological saline (No.
- Ribosome PC PS DCP compound (3) Formulation 1 50 nmol 50 nmol 10 nmol 40 nmol Formulation 2 50 nmol 50 nmol 10 nmol 75 nmol Formulation 3 50 nmol 50 nmol 10 nmol 150 nmol
- Example 6 Selective uptake of ribosome preparations by vascular smooth muscle cells (1)
- Example 5 The three types of ribosomes prepared in Example 5 were added to the smooth muscle cell culture system shown in FIG. 1 or 2 of Example 1 at the following times (2), (3), or (3), and the culture was continued.
- Example 9 In the vascular smooth muscle culture system using rat (Fig. 3) and) heron (Fig. 4) cells created in Example 4, the three types of ribosomes prepared in Example 5 were subjected to the timing of (1), (2), or (3) above. And culture was continued. The amount of compound (3) taken up into the cells was quantified by HPLC. The results are shown in FIGS. 7 and 8, and in all cases, the same results as in FIG. 5 for the mouse cells were obtained.
- Example 9 Example 9
- the ribosome of the present invention can accumulate an eodo compound on vascular smooth muscle cells that abnormally grow under the influence of foamed macrophages, and selectively image a lesion of a vascular disease caused by abnormal growth of vascular smooth muscle.
- Angled as an X-ray contrast agent for Further, the culture system provided by the method for producing a culture system of the present invention can be used for in vitro screening of pharmaceuticals and the like as a cell culture system that reproduces the state of a lesion such as an atherosclerotic lesion or restenosis.
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Manufacturing Of Micro-Capsules (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001252603A AU2001252603B2 (en) | 2000-04-28 | 2001-04-26 | Liposomes containing hydrophobic iodo compound |
CA002407654A CA2407654C (en) | 2000-04-28 | 2001-04-26 | Liposome containing hydrophobic iodine compound |
NZ522457A NZ522457A (en) | 2000-04-28 | 2001-04-26 | Liposomes containing hydrophobic iodo compound |
AU5260301A AU5260301A (en) | 2000-04-28 | 2001-04-26 | Liposomes containing hydrophobic iodo compound |
US10/258,801 US7101532B2 (en) | 2000-04-28 | 2001-04-26 | Liposome containing hydrophobic iodine compound |
DE60128800T DE60128800T2 (de) | 2000-04-28 | 2001-04-26 | Hydrophobe iodverbindung enthaltende liposome |
EP01925960A EP1284146B1 (en) | 2000-04-28 | 2001-04-26 | Liposomes containing hydrophobic iodo compound |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000130069 | 2000-04-28 | ||
JP2000-130069 | 2000-04-28 | ||
JP2001-18573 | 2001-01-26 | ||
JP2001018573 | 2001-01-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001082977A1 true WO2001082977A1 (fr) | 2001-11-08 |
Family
ID=26591162
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2001/003629 WO2001082977A1 (fr) | 2000-04-28 | 2001-04-26 | Liposomes contenant un compose iodo hydrophobe |
Country Status (9)
Country | Link |
---|---|
US (1) | US7101532B2 (ja) |
EP (1) | EP1284146B1 (ja) |
KR (1) | KR100824068B1 (ja) |
AT (1) | ATE363920T1 (ja) |
AU (2) | AU2001252603B2 (ja) |
CA (1) | CA2407654C (ja) |
DE (1) | DE60128800T2 (ja) |
NZ (1) | NZ522457A (ja) |
WO (1) | WO2001082977A1 (ja) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1287833A2 (en) * | 2001-08-20 | 2003-03-05 | Fuji Photo Film Co., Ltd. | Liposome containing hydrophobic iodine compound and X-ray contrast medium comprising said liposome |
EP1402884A1 (en) * | 2002-09-25 | 2004-03-31 | Fuji Photo Film Co. Ltd. | Liposome-containing remedy for the treatment of vascular diseases |
JP2018062475A (ja) * | 2016-10-11 | 2018-04-19 | 学校法人 聖マリアンナ医科大学 | 非イオン性ヨード造影剤の結合体 |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE382033T1 (de) * | 2001-08-23 | 2008-01-15 | Fujifilm Corp | 1,3-glyceridverbindung mit zwei iodphenylgruppen |
JP2004064636A (ja) * | 2002-07-31 | 2004-02-26 | Fuji Photo Film Co Ltd | サブトラクション画像形成方法 |
US7216038B2 (en) | 2003-09-11 | 2007-05-08 | Franco Vitaliano | Quantum information processing elements and quantum information processing platforms using such elements |
US7219017B2 (en) | 2003-09-11 | 2007-05-15 | Franco Vitaliano | Quantum information processing elements and quantum information processing platforms using such elements |
US7219018B2 (en) * | 2003-09-11 | 2007-05-15 | Franco Vitaliano | Quantum information processing elements and quantum information processing platforms using such elements |
US7393924B2 (en) * | 2004-01-06 | 2008-07-01 | Franco Vitaliano | Smart bio-nanoparticle elements |
US20060239925A1 (en) * | 2005-04-21 | 2006-10-26 | Konica Minolta Medical & Graphic, Inc. | Method of manufacturing pharmaceutical preparation containing liposomes |
JP2006335745A (ja) * | 2005-06-06 | 2006-12-14 | Fujifilm Holdings Corp | リポソームを含むmri造影剤 |
US11235062B2 (en) * | 2009-03-06 | 2022-02-01 | Metaqor Llc | Dynamic bio-nanoparticle elements |
US11096901B2 (en) | 2009-03-06 | 2021-08-24 | Metaqor Llc | Dynamic bio-nanoparticle platforms |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021384A1 (en) * | 1991-06-03 | 1992-12-10 | Karlshamns Lipidteknik Ab | X-ray contrast agent |
WO1996024381A2 (de) * | 1995-02-09 | 1996-08-15 | Schering Aktiengesellschaft | Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes |
WO1996025955A1 (en) * | 1995-02-24 | 1996-08-29 | Bracco Research S.A. | Liposome suspensions as blood pool imaging contrast agents |
WO1996028414A1 (en) * | 1995-03-09 | 1996-09-19 | Nanosystems L.L.C. | Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4192859A (en) * | 1978-09-29 | 1980-03-11 | E. R. Squibb & Sons, Inc. | Contrast media containing liposomes as carriers |
GB2157283B (en) * | 1984-03-30 | 1987-07-08 | Squibb & Sons Inc | Esters of 3,5-diacetylamino-2,4,6-triiodobenzoic acid as x-ray contrast agents |
-
2001
- 2001-04-26 NZ NZ522457A patent/NZ522457A/en not_active IP Right Cessation
- 2001-04-26 KR KR1020027014403A patent/KR100824068B1/ko not_active IP Right Cessation
- 2001-04-26 DE DE60128800T patent/DE60128800T2/de not_active Expired - Lifetime
- 2001-04-26 CA CA002407654A patent/CA2407654C/en not_active Expired - Fee Related
- 2001-04-26 US US10/258,801 patent/US7101532B2/en not_active Expired - Lifetime
- 2001-04-26 AU AU2001252603A patent/AU2001252603B2/en not_active Ceased
- 2001-04-26 AT AT01925960T patent/ATE363920T1/de not_active IP Right Cessation
- 2001-04-26 EP EP01925960A patent/EP1284146B1/en not_active Expired - Lifetime
- 2001-04-26 AU AU5260301A patent/AU5260301A/xx active Pending
- 2001-04-26 WO PCT/JP2001/003629 patent/WO2001082977A1/ja active IP Right Grant
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992021384A1 (en) * | 1991-06-03 | 1992-12-10 | Karlshamns Lipidteknik Ab | X-ray contrast agent |
WO1996024381A2 (de) * | 1995-02-09 | 1996-08-15 | Schering Aktiengesellschaft | Kontrastmittelhaltige liposomen für die darstellung des intravasalraumes |
WO1996025955A1 (en) * | 1995-02-24 | 1996-08-29 | Bracco Research S.A. | Liposome suspensions as blood pool imaging contrast agents |
WO1996028414A1 (en) * | 1995-03-09 | 1996-09-19 | Nanosystems L.L.C. | Nanoparticulate diagnostic triiodo benzoate derivatives as x-ray contrast agents for blood pool and lymphatic system imaging |
Non-Patent Citations (1)
Title |
---|
XIAO W. ET AL.: "Radiolabeled cholesteryl iopanoate/acetylated low density lipoprotein as a potential probe for visualization of early atheroscelerotic lesions in rabbits", PHARM. RES., vol. 16, no. 3, 1999, pages 420 - 426, XP002942252 * |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1287833A2 (en) * | 2001-08-20 | 2003-03-05 | Fuji Photo Film Co., Ltd. | Liposome containing hydrophobic iodine compound and X-ray contrast medium comprising said liposome |
EP1287833A3 (en) * | 2001-08-20 | 2003-04-23 | Fuji Photo Film Co., Ltd. | Liposome containing hydrophobic iodine compound and X-ray contrast medium comprising said liposome |
US7008614B2 (en) | 2001-08-20 | 2006-03-07 | Fuji Photo Film Co., Ltd. | Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome |
EP1402884A1 (en) * | 2002-09-25 | 2004-03-31 | Fuji Photo Film Co. Ltd. | Liposome-containing remedy for the treatment of vascular diseases |
JP2018062475A (ja) * | 2016-10-11 | 2018-04-19 | 学校法人 聖マリアンナ医科大学 | 非イオン性ヨード造影剤の結合体 |
Also Published As
Publication number | Publication date |
---|---|
CA2407654C (en) | 2009-06-30 |
ATE363920T1 (de) | 2007-06-15 |
AU2001252603B2 (en) | 2005-10-13 |
AU5260301A (en) | 2001-11-12 |
EP1284146A1 (en) | 2003-02-19 |
EP1284146B1 (en) | 2007-06-06 |
CA2407654A1 (en) | 2002-10-28 |
KR100824068B1 (ko) | 2008-04-21 |
DE60128800D1 (de) | 2007-07-19 |
NZ522457A (en) | 2004-07-30 |
DE60128800T2 (de) | 2008-02-07 |
KR20020093957A (ko) | 2002-12-16 |
US20030180220A1 (en) | 2003-09-25 |
US7101532B2 (en) | 2006-09-05 |
EP1284146A4 (en) | 2004-12-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20240148913A1 (en) | Liposomal nanocarrier delivery system for targeting active cd44 molecule,preparation method therefor, and uses thereof | |
JP6483017B2 (ja) | ナノ粒子製剤 | |
WO2001082977A1 (fr) | Liposomes contenant un compose iodo hydrophobe | |
RU2637372C2 (ru) | Средство для лечения фиброза кишечника | |
US7008614B2 (en) | Liposome containing hydrophobic iodine compound and X-ray contrast medium for radiograph comprising the liposome | |
Barazza et al. | The complex fate in plasma of gadolinium incorporated into high-density lipoproteins used for magnetic imaging of atherosclerotic plaques | |
JP2003055267A (ja) | 疎水性の放射性ヨード化合物を含むリポソーム | |
JP2003055196A (ja) | 疎水性ヨード化合物を含むリポソーム及び該リポソームを含むx線造影剤 | |
JP2005170807A (ja) | 抗体を含むリポソーム | |
JP2004115378A (ja) | 水溶性ヨード化合物を含むリポソーム | |
JP2004292363A (ja) | ヨードアリール基を有するリン酸エステル誘導体 | |
JP5053601B2 (ja) | ビス(トリフルオロメチル)フェニル基を有するステロイド化合物 | |
US20030064415A1 (en) | Method for preparing cell culture system | |
JP2007181414A (ja) | 血小板による血管壁障害の作成方法 | |
JP2003055268A (ja) | 疎水性ヨード化合物を含有するリポソームを含むx線造影剤 | |
JP2011513401A (ja) | フラーレンを投与することにより動脈プラークの蓄積を抑制するための方法 | |
JP2004292362A (ja) | ヨードアリール基を有する炭酸エステル誘導体 | |
JP2004359579A (ja) | ヨード原子とアセタール構造を有するステロイド化合物 | |
JP2004137203A (ja) | ヨードフェニル基を有する1,2−および1,3−グリセリド化合物 | |
JP2004231623A (ja) | ヨードアリール基を有するスレイトール誘導体 | |
JP2004231625A (ja) | ヨード基を有するフタル酸誘導体 | |
JP2003128591A (ja) | 疎水性ヨード化合物を含むリポソームの製剤方法とこれを用いたリポソーム製剤 | |
JP2005035942A (ja) | ヨードアリール基を有するステロイド化合物 | |
JP2004115397A (ja) | 血管疾患治療薬を含むリポソーム | |
JP2004359580A (ja) | ヨードアリール基を有するピラノース誘導体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 579850 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020027014403 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001252603 Country of ref document: AU Ref document number: 2407654 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 522457 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001925960 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1020027014403 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2001925960 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10258801 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 522457 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 522457 Country of ref document: NZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001252603 Country of ref document: AU |
|
WWG | Wipo information: grant in national office |
Ref document number: 2001925960 Country of ref document: EP |